At a glance
- Originator Fujisawa
- Class Antiandrogens; Antineoplastics
- Mechanism of Action Testosterone congener inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 19 May 1998 Profile reviewed
- 19 May 1998 No-Development-Reported for Cancer in Japan (Unknown route)